Prostate Cancer Daily

June 15, 2026

Videos

Peer-to-Peer Clinical Conversations

Prior Therapy, Genomics, and Patient Factors in mCRPC Treatment Selection - Kristine Lacuna

Kristine Peregrino Lacuna

Kristine Lacuna discusses mCRPC treatment selection with Neeraj Agarwal, organizing patients into those who have and have not received a prior ARPI.

View

FDA Approval of Capivasertib with Abiraterone and Prednisone in PTEN-Deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer: Expert Panel Discussion

Elisabeth Heath

Neeraj Agarwal hosts a discusion with Elisabeth Heath, Hope Rugo, and Daniel George on the CAPItello-281 trial.

View

Beyond the Abstracts

Inflammation and Insulin Profiles in Men Assigned to Exercise vs. Usual Care for Prostate Cancer: Results from the Active Surveillance Exercise (ASX) Randomized Controlled Trial - Beyond the Abstract

Rechallenge and Extended [177Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer - Beyond the Abstract

Conference Coverage

SNMMI 2026: Predicting Early PSA Response to 177Lu-PSMA Therapy using Baseline PET Imaging Biomarkers and Cycle 1 Dosimetry

ASCO 2026: EORTC GUCG 2238 – DE-ESCALATE: A Pragmatic Trial to Revisit Intermittent ADT in mHSPC in the Era of New ARPIs

ASCO 2026: ctDNA-Based Clinical-Genetic Prognostic Model for rPFS in Patients with mCRPC: Analysis of Alliance A031201

AUA 2026: Utility of PROSTest, a Novel Blood-based mRNA assay, for Predicting Outcome to 177LuPSMA Radioligand Therapy

AUA 2026: IRRADIANT: Irreversible Electroporation versus Radiation Boost for Intermediate Risk Prostate Cancer

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.

PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy.

Phenotyping Prostate Cancer in a National Health System Using Large Language Models.

Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.

Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.

Expression of progranulin (GP88) protein appears as an independent prognostic factor for clinical progression in high-risk prostate cancer patients.

How Will PSMAddition Impact the Management of Prostate Cancer?

FDA Approves Truqap Combination for PTEN-Deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer

LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract

Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login